Suicide PreventionBridge the GapNCT06880809
Bridge the Gap (BTG) - Black Youth Group
A study testing Bridge the Gap (BTG) - Black Youth Group in people with Suicide Prevention, run by Children's Hospital Los Angeles at 1 site in United States.
Trial summary
The goal of this clinical trial is to develop and preliminarily test a culturally adapted suicide intervention specifically for black youth. The main question it aims to answer: -To evaluate the feasibility and acceptability of the group, as well as the preliminary efficacy of the group for decreasing suicidal… Read more about this study
- Who is it for?
- Ages 12 to 17 yearsHealthy volunteers can take part
- Conditions the study is for
- Suicide Prevention
- What is being tested?
- Bridge the Gap (BTG) - Black Youth Group
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 16 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Jun 2025to 1 Jun 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 12 to 17 years
- All sexes
- Healthy volunteers accepted
- Child
Who may be able to join
- 12-17 years old
- Identify as Black or African American or being of African descent
- Have current suicidal ideation or suicidal ideation within the last 30 days
- Have assent from the adolescent participant and consent from an individual's caregiver or guardian to participate.
Who cannot join
- An active psychotic disorder or current psychosis symptoms
- No history of suicide attempt(s) or suicide ideation in the past 30 days
- Cognitive deficits or a medical condition diagnosed from a medical provider that precludes full understanding of study materials as assessed through an inability to complete the pre-treatment CAMS SSF \& SSP
- Caregivers, guardians, and/or the patient refuse to participate.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Children's Hospital Los Angeles
Los Angeles, California, 90027
Tia Tyndal, Ph.D., 323-361-4648, ttyndal@chla.usc.edu
Tia Tyndal, Ph.D.
About this study
Official title: Bridging the Gap: A Collaborative Intervention Group for Black Youth at Risk for Suicide
The goal of this clinical trial is to develop and preliminarily test a culturally adapted suicide intervention specifically for black youth. The main question it aims to answer:
-To evaluate the feasibility and acceptability of the group, as well as the preliminary efficacy of the group for decreasing suicidal thoughts and behaviors and increasing protective factors such as hope, positive ethnic identity, and family and peer support.
Participants will be asked to attend 10-week group intervention and complete pre-treatment and post-treatment assessment measures.
- Conditions
- Suicide Prevention
- Being tested
- Bridge the Gap (BTG) - Black Youth Group
- Keywords
- Suicide Prevention, Black Youth, Collaborative Assessment & Management of Suicidality (CAMS), Group Intervention
- Medical subject headings
- Suicide Prevention
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Bridge the Gap (BTG) - Black Youth GroupBehavioural
Participants will complete a group intervention, rooted in the Collaborative Assessment \& Management of Suicidality (CAMS) evidence-based model, driven by their own unique identification of suicide drivers.
| Study group | Role | What they receive |
|---|---|---|
| Treatment Arm | Experimental | Participants will complete a 10-week group and complete pre-treatment and post-treatment assessment measures. Receives: Behavioral: Bridge the Gap (BTG) - Black Youth Group |
What is being measured
The primary outcome is the main question the study is designed to answer.
The Collaborative Assessment & Management of Suicidality - Suicide Status Form (SSF)
An assessment of suicide risk that consists of six core assessment constructs: psychological pain, stress, agitation, hopelessness, self-hate, and overall risk of suicide; as well as reasons for living and reasons for dying constructs, and wish to live and wish to die constructs.
Measured: From pre-treatment until 3 months post-treatment, approximately 23 weeks.
Ethnic Identity Scale (EIS)
A 17-item scale that assesses the three components of ethnic identity and distinguishes between exploration, resolution, and affirmation. Scores range from 17-68, with higher scores indicating higher levels of affirmation, exploration, and resolution.
Measured: From baseline until 3 months post-treatment, approximately 22 weeks.
Living Ladder Scale
A one-item measure that is prospectively associated with suicidal ideation and suicide attempts by measuring readiness to continue living among individuals thinking of suicide. Scores range from 0-8, with 8 indicating an individual is committed to making changes to make their lives worth living.
Measured: From baseline until 3 months post-treatment, approximately 22 weeks.
Brief Suicide Cognitions Scale (B-SCS)
A 6-item self-report scale that measures the suicidal belief system, including dimensions of unlovability, unbearability, and unsolvability. Scores range from 6-30, with lower scores indicating fewer suicide cognitions.
Measured: From baseline until 3 months post-treatment, approximately 22 weeks.
Therapeutic Relationship Working Alliance Inventory, Short Revised (WAI-SR)
A 12-item scale that reflects Bordin's three-dimensional conceptualization of therapeutic alliance: task, goal, and bond. Scores range from 12-60, with higher scores indicating higher therapeutic alliance.
Measured: From baseline until 3 months post-treatment, approximately 22 weeks.
Optimism and Hope Scale (OHS)
A 14-item scale that measures an individual's level of both optimism, as characterized by a positive outlook on the future, and hope, as characterized by the belief in one's ability to achieve goals and navigate challenges. Scores range from 14-56, with lower scores indicating more hope and optimism.
Measured: From baseline until 3 months post-treatment, approximately 22 weeks.
Parent Readiness for Hospital Discharge Scale (RHDS)
A 23-item scale aimed at providing a discharge readiness assessment before pediatric discharge from care in hospital settings. Scores range from 0-80, with higher scores indicating more readiness.
Measured: From baseline until 3 months post-treatment, approximately 22 weeks.
Group Cohesion Scale
A 12-item self-report scale that measures group cohesion, including dimensions of engagement, conflict, and avoidance. Scores across the subscales range from 0-72; higher scores indicate more of that dimension.
Measured: From baseline until the beginning of post-treatment, approximately 10 weeks.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Mar 2025
- Study start1 Jun 2025
- Primary completion1 Jan 2027 (estimated)
- Study completion1 Jun 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Suicide PreventionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 16 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Children's Hospital Los Angeles
- Sponsor type
- University, hospital or other
- Collaborators
- American Psychological Foundation
- Responsible party
- Principal investigator, Tia Tyndal, Children's Hospital Los Angeles
- Investigators
- Tia Tyndal, PhD, Principal investigator, Children's Hospital Los Angeles
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06880809
- Sponsor's protocol ID
- CHLA-25-00072
- Acronym
- Bridge the Gap
- Status last verified
- Apr 2026
- First submitted
- 12 Mar 2025
- Last updated
- 30 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 30 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Bridging the Gap: A Collaborative Intervention Group for Black Youth at Risk for Suicide
- ClinicalTrials.gov ID
- NCT06880809
- Acronym / sponsor ID
- Bridge the Gap / CHLA-25-00072
- Conditions
- Suicide Prevention
- Keywords
- Suicide Prevention, Black Youth, Collaborative Assessment & Management of Suicidality (CAMS), Group Intervention
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 16 participants (estimated)
- Lead sponsor
- Children's Hospital Los AngelesUniversity, hospital or other
- Collaborators
- American Psychological Foundation
- Study start
- 1 Jun 2025 (actual)
- Primary completion
- 1 Jan 2027 (estimated)
- Study completion
- 1 Jun 2027 (estimated)
- First posted
- 18 Mar 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to develop and preliminarily test a culturally adapted suicide intervention specifically for black youth. The main question it aims to answer:
-To evaluate the feasibility and acceptability of the group, as well as the preliminary efficacy of the group for decreasing suicidal thoughts and behaviors and increasing protective factors such as hope, positive ethnic identity, and family and peer support.
Participants will be asked to attend 10-week group intervention and complete pre-treatment and post-treatment assessment measures.
Study design
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Treatment Arm | Experimental | Behavioral: Bridge the Gap (BTG) - Black Youth GroupParticipants will complete a 10-week group and complete pre-treatment and post-treatment assessment measures. |
Who may qualify
- Ages
- 12 to 17 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child
Key inclusion criteria (4 listed)
- 12-17 years old
- Identify as Black or African American or being of African descent
- Have current suicidal ideation or suicidal ideation within the last 30 days
- Have assent from the adolescent participant and consent from an individual's caregiver or guardian to participate.
Key exclusion criteria (4 listed)
- An active psychotic disorder or current psychosis symptoms
- No history of suicide attempt(s) or suicide ideation in the past 30 days
- Cognitive deficits or a medical condition diagnosed from a medical provider that precludes full understanding of study materials as assessed through an inability to complete the pre-treatment CAMS SSF \& SSP
- Caregivers, guardians, and/or the patient refuse to participate.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Bridge the Gap (BTG) - Black Youth GroupParticipants will complete a group intervention, rooted in the Collaborative Assessment \& Management of Suicidality (CAMS) evidence-based model, driven by their own unique identification of suicide drivers. | Behavioural | Treatment Arm |
Primary outcome
The Collaborative Assessment & Management of Suicidality - Suicide Status Form (SSF)
Time frame: From pre-treatment until 3 months post-treatment, approximately 23 weeks.
An assessment of suicide risk that consists of six core assessment constructs: psychological pain, stress, agitation, hopelessness, self-hate, and overall risk of suicide; as well as reasons for living and reasons for dying constructs, and wish to live and wish to die constructs.
Ethnic Identity Scale (EIS)
Time frame: From baseline until 3 months post-treatment, approximately 22 weeks.
A 17-item scale that assesses the three components of ethnic identity and distinguishes between exploration, resolution, and affirmation. Scores range from 17-68, with higher scores indicating higher levels of affirmation, exploration, and resolution.
Living Ladder Scale
Time frame: From baseline until 3 months post-treatment, approximately 22 weeks.
A one-item measure that is prospectively associated with suicidal ideation and suicide attempts by measuring readiness to continue living among individuals thinking of suicide. Scores range from 0-8, with 8 indicating an individual is committed to making changes to make their lives worth living.
Brief Suicide Cognitions Scale (B-SCS)
Time frame: From baseline until 3 months post-treatment, approximately 22 weeks.
A 6-item self-report scale that measures the suicidal belief system, including dimensions of unlovability, unbearability, and unsolvability. Scores range from 6-30, with lower scores indicating fewer suicide cognitions.
Therapeutic Relationship Working Alliance Inventory, Short Revised (WAI-SR)
Time frame: From baseline until 3 months post-treatment, approximately 22 weeks.
A 12-item scale that reflects Bordin's three-dimensional conceptualization of therapeutic alliance: task, goal, and bond. Scores range from 12-60, with higher scores indicating higher therapeutic alliance.
Optimism and Hope Scale (OHS)
Time frame: From baseline until 3 months post-treatment, approximately 22 weeks.
A 14-item scale that measures an individual's level of both optimism, as characterized by a positive outlook on the future, and hope, as characterized by the belief in one's ability to achieve goals and navigate challenges. Scores range from 14-56, with lower scores indicating more hope and optimism.
Parent Readiness for Hospital Discharge Scale (RHDS)
Time frame: From baseline until 3 months post-treatment, approximately 22 weeks.
A 23-item scale aimed at providing a discharge readiness assessment before pediatric discharge from care in hospital settings. Scores range from 0-80, with higher scores indicating more readiness.
Group Cohesion Scale
Time frame: From baseline until the beginning of post-treatment, approximately 10 weeks.
A 12-item self-report scale that measures group cohesion, including dimensions of engagement, conflict, and avoidance. Scores across the subscales range from 0-72; higher scores indicate more of that dimension.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Apr 2026.
- Individual participant dataSharing planned: No
Related trials for Suicide Prevention
Not yet recruitingPhase 1/2
Reducing Firearm Suicide Among Veterans: Evaluating the Effectiveness of Peer-Delivered Lethal Means Counseling
Suicide, Secure Firearm Storage
Not yet recruitingPhase 2
Intravenous Ketamine for Acute Suicidal Crisis and Psychiatric Hospital Length of Stay
Suicidal Ideation, Suicidal Behavior
Recruiting
Developing a Recovery-Oriented Suicide Prevention Program for Young People at Clinical High Risk for Psychosis
Clinical High Risk for Psychosis (CHR), Suicidal Ideation
Recruiting
Evaluation of a Multi-Layered Digital Phenotyping, Digital Safety Plan, and Pharmacogenomic Intervention for Suicide Prevention in Adults With Depression
Depressive Disorder, Major Depressive Disorder, Suicidal Ideation
Not yet recruiting
THRIVE: A Recovery-Focused Suicide Prevention Intervention in Crisis Stabilization Centers
Suicide
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Tia Tyndal, PhD principal investigator
Children's Hospital Los Angeles
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Bridge the Gap (BTG) - Black Youth Group in people with Suicide Prevention, run by Children's Hospital Los Angeles at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 30 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Tia Tyndal, PhD (323-361-4648, ttyndal@chla.usc.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The Collaborative Assessment & Management of Suicidality - Suicide Status Form (SSF) (time frame: From pre-treatment until 3 months post-treatment, approximately 23 weeks.). The study lists 8 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Apr 2026.